[1] |
George A, Mani V, Noufal A. Update on the classification of hemangioma[J]. J Oral Maxillofac Pathol, 2014, 18(Suppl 1): S117⁃120. DOI: 10.4103/0973⁃029X.141321.
|
[2] |
Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature[J]. Pediatr Dermatol, 2008, 25(2): 168⁃173. DOI: 10.1111/j.1525⁃1470.2008.00626.x.
|
[3] |
Hoornweg MJ, Smeulders MJ, Ubbink DT, et al. The prevalence and risk factors of infantile haemangiomas: a case⁃control study in the Dutch population[J]. Paediatr Perinat Epidemiol, 2012, 26(2): 156⁃162. DOI: 10.1111/j.1365⁃3016.2011.01214.x.
|
[4] |
Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy[J]. Pediatrics, 2013, 131(1): 99⁃108. DOI: 10.1542/peds.2012⁃1128.
|
[5] |
Luu M, Frieden IJ. Haemangioma: clinical course, complications and management[J]. Br J Dermatol, 2013, 169(1): 20⁃30. DOI: 10.1111/bjd.12436.
|
[6] |
Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management[J]. Pediatrics, 2008, 122(2): 360⁃367. DOI: 10.1542/peds.2007⁃2767.
|
[7] |
Léauté⁃Labrèze C, de la Roque ED, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(24): 2649⁃2651. DOI: 10.1056/NEJMc0708819.
|
[8] |
de Graaf M, Raphael MF, Breugem CC, et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group[J]. J Plast Reconstr Aesthet Surg, 2013, 66(12): 1732⁃1740. DOI: 10.1016/j.bjps.2013.07.035.
|
[9] |
Léauté⁃Labrèze C, Hoeger P, Mazereeuw⁃Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma[J]. N Engl J Med, 2015, 372(8): 735⁃746. DOI: 10.1056/NEJMoa1404710.
|
[10] |
de Graaf M, Breur JM, Raphaël MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants[J]. J Am Acad Dermatol, 2011, 65(2): 320⁃327. DOI: 10.1016/j.jaad.2010.06.048.
|
[11] |
Metry D, Heyer G, Hess C, et al. Consensus statement on diagnostic criteria for PHACE syndrome[J]. Pediatrics, 2009, 124(5): 1447⁃1456. DOI: 10.1542/peds.2009⁃0082.
|
[12] |
Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies[J]. J Pediatr, 2010, 157(5): 795⁃801.e1⁃7. DOI: 10.1016/j.jpeds.2010.05.027.
|
[13] |
Janmohamed SR, de Waard⁃van der Spek FB, Madern GC, et al. Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS)[J]. Clin Exp Dermatol, 2011, 36(7): 715⁃723. DOI: 10.1111/j.1365⁃2230.2011.04080.x.
|
[14] |
Janmohamed SR, van Oosterhout M, de Laat PC, et al. Scoring the therapeutic effects of oral propranolol for infantile hemangioma: a prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS)[J]. J Am Acad Dermatol, 2015, 73(2): 258⁃263. DOI: 10.1016/j.jaad.2015. 05.012.
|
[15] |
Ji Y, Chen S, Xu C, et al. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action[J]. Br J Dermatol, 2015, 172(1): 24⁃32. DOI: 10.1111/bjd.13388.
|